Correlation Between Glycolytic Phenotype and Tumor Grade in Soft-Tissue Sarcomas by 18F-FDG PET

被引:50
作者
Benz, Matthias R. [2 ]
Dry, Sarah M. [3 ]
Eilber, Fritz C. [1 ,4 ]
Allen-Auerbach, Martin S. [1 ]
Tap, William D. [5 ]
Elashoff, David [6 ]
Phelps, Michael E. [1 ]
Czernin, Johannes [1 ]
机构
[1] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Ahmanson Biol Imaging Div, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Freiburg, Dept Nucl Med, D-7800 Freiburg, Germany
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Div Surg Oncol, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Med Oncol, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA
关键词
sarcoma; PET; F-18-FDG; glycolytic phenotype; POSITRON-EMISSION-TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; CANCER-CENTERS-SARCOMA; NERVE SHEATH TUMORS; TERM-FOLLOW-UP; FDG-PET; FRENCH-FEDERATION; CLINICOPATHOLOGICAL ANALYSIS; RETROSPECTIVE ANALYSIS; PROGNOSTIC VARIABLES;
D O I
10.2967/jnumed.109.074229
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Tumor glycolytic phenotyping can be accomplished with F-18-FDG PET. Tumor F-18-FDG uptake correlates with tumor grade in several cancers. However, the role of F-18-FDG PET for the grading of soft-tissue sarcomas (STSs) warrants further research. Methods: One hundred two patients (48 men and 54 women; mean age +/- SD, 50 +/- 17 y) with 12 STS subtypes underwent F-18-FDG PET/CT before treatment. Tumor F-18-FDG uptake, expressed as maximum standardized uptake value (SUVmax), was compared among subtypes and correlated with histopathologic grade. Two frequently used sarcoma grading systems-the 3-tier system of the French Federation of Cancer Centers Sarcoma Group (Federation Nationale des Centres de Lutte Contre le Cancer [FNCLCC]) and a 2-tier system (low grade vs. high grade)-were used. Results: More than 90% of STSs (93/102) exhibited a strong glycolytic phenotype (SUV-max, 2.7-52.2 g/mL). Tumor SUVmax differed significantly among tumor grades (P < 0.001 for the 3- and 2-tier grading systems). The FNCLCC and 2-tier grading systems predicted tumor grade with similar accuracy (area under the curve, 0.83 and 0.85, respectively; P = 0.35). SUVmax differed significantly among histologic subtypes (P = 0.03) in the entire population but not when high-grade STSs were analyzed separately (P = 0.31). Conclusion: The tumor glycolytic phenotype correlated significantly with histologic grade as determined by both the FNCLCC and 2-tier (high vs. low) grading systems. F-18-FDG PET cannot be used to reliably distinguish among grade 2 and 3 STSs (by FNCLCC) and the various subtypes.
引用
收藏
页码:1174 / 1181
页数:8
相关论文
共 41 条
[1]   The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis [J].
Bastiaannet, E ;
Groen, H ;
Jager, PL ;
Cobben, DCP ;
van der Graaf, WTA ;
Vaalburg, W ;
Hoekstra, HJ .
CANCER TREATMENT REVIEWS, 2004, 30 (01) :83-101
[2]   Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas:: Interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors [J].
Benz, Matthias R. ;
Evilevitch, Vladimir ;
Allen-Auerbach, Martin S. ;
Eilber, Fritz C. ;
Phelps, Michael E. ;
Czernin, Johannes ;
Weber, Wolfgang A. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (07) :1038-1046
[3]   Quantitative F18-Fluorodeoxyglucose Positron Emission Tomography Accurately Characterizes Peripheral Nerve Sheath Tumors as Malignant or Benign [J].
Benz, Matthias R. ;
Czernin, Johannes ;
Dry, Sarah M. ;
Tap, William D. ;
Allen-Auerbach, Martin S. ;
Elashoff, David ;
Phelps, Michael E. ;
Weber, Wolfgang A. ;
Eilber, Fritz C. .
CANCER, 2010, 116 (02) :451-458
[4]   FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas [J].
Benz, Matthias R. ;
Czernin, Johannes ;
Allen-Auerbach, Martin S. ;
Tap, William D. ;
Dry, Sarah M. ;
Elashoff, David ;
Chow, Kira ;
Evilevitch, Vladimir ;
Eckardt, Jeff J. ;
Phelps, Michael E. ;
Weber, Wolfgang A. ;
Eilber, Fritz C. .
CLINICAL CANCER RESEARCH, 2009, 15 (08) :2856-2863
[5]   FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients [J].
Brenner, W ;
Conrad, EU ;
Eary, JF .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (02) :189-195
[6]   Risk assessment in liposarcoma patients based on FDG PET imaging [J].
Brenner, Winfried ;
Eary, Janet F. ;
Hwang, Willy ;
Vernon, Cheryl ;
Conrad, Ernest U. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (11) :1290-1295
[7]   Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine [J].
Buck, Andreas K. ;
Herrmann, Ken ;
zum Bueschenfelde, Christian Meyer ;
Juweid, Malik E. ;
Bischoff, Mark ;
Glatting, Gerhard ;
Weirich, Gregor ;
Moeller, Peter ;
Wester, Hans-Juergen ;
Scheidhauer, Klemens ;
Dechow, Tobias ;
Peschel, Christian ;
Schwaiger, Markus ;
Reske, Sven N. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :2970-2977
[8]  
CHAREST M, 2009, EUR J NUCL MED 0711
[9]  
Coindre JM, 2006, ARCH PATHOL LAB MED, V130, P1448
[10]   Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group [J].
Coindre, JM ;
Terrier, P ;
Bui, NB ;
Bonichon, F ;
Collin, F ;
LeDoussal, V ;
Mandard, AM ;
Vilain, MO ;
Jacquemier, J ;
Duplay, H ;
Sastre, X ;
Barlier, C ;
HenryAmar, M ;
Lesech, JM ;
Contesso, G .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :869-877